<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors analyze the progress achieved in the treatment of low-grade as well as of high-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The challenging task in the treatment of low-grade or indolent <z:hpo ids='HP_0002665'>lymphomas</z:hpo> still is to decide whether watchful waiting is sufficient or whether chemotherapy is necessary and how aggressive this treatment should be </plain></SENT>
<SENT sid="2" pm="."><plain>Among the new chemotherapeutic agents the role of <z:chebi fb="0" ids="35584">purine</z:chebi> analogues should be emphasized, fludarabin is especially important in the treatment of <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, while pentostatin and cladribine have revolutionized the treatment of hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with monoclonal antibodies, radioimmunoconjugates as well as autologous or allogeneic stem cell transplantation are potential new therapeutic options in the treatment of low-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In the case of aggressive non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> risk-adapted strategies help the choice between standard or more intensive treatment options </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with relapsed high-grade <z:hpo ids='HP_0002665'>lymphomas</z:hpo> stem cell transplantation is indicated </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> the combination of hyperCVAD protocol + stem cell transplantation greatly improves prognosis </plain></SENT>
</text></document>